Email This Article

Headlines & Perspectives
Genentech's Avastin Might Renew Interest in Tumor Battle
By Adam Feuerstein
10/31/01 - 08:40 AM EST
Three years after an overhyped rollout, drugs that attack tumors' blood supplies are making progress.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,197.09 1,087.23 2,149.02 34.46
Oil *
75.93
DOWN
94.17
DOWN
11.28
DOWN
17.88
DOWN
0.28
10 Yr
3.45%
SPDR Gold
108.21
-0.92%
-1.03%
-0.83%
-0.81%
Data delayed 20 minutes

Brokerage Partners